Not well understood; androgen excess may play a role, and genetic predisposition is suspected.
Transformation of the terminal hair follicle to a thinner hair.
Diffuse thinning of hair, thinned frontal hairline, progressively widening midline part, and preserved hair density in the occipital region.
Based on history and exam; laboratory tests include free and total testosterone level and dehydroepiandrosterone sulfate (DHEAS) level.
Topical minoxidil.
It is an aldosterone antagonist that competitively blocks androgen receptors and inhibits androgen synthesis.
It inhibits the conversion of testosterone to DHT (dihydrotestosterone).
Teratogenic (risk category X).
A chronic, relapsing autoimmune disorder in which the immune system targets hair follicles, causing non-scarring hair loss.
An autoimmune disease where hair follicles transition prematurely from the growth phase to non-growth phases; genetic predisposition also plays a role.
Intralesional corticosteroid injections or potent topical corticosteroids if injections are not tolerated.
They inhibit the JAK/STAT pathway, resulting in immunologic changes that prolong the growth phase and stimulate hair stem cell proliferation.
Pain at injection sites, localized skin atrophy, hypopigmentation, and potential relapses upon treatment discontinuation.
Anthralin topical.
1 of 14
Explore the causes, symptoms, and treatment options for female pattern hair loss, including the role of androgens, genetic factors, and effective therapies like minoxidil and spironolactone.
1. What is a suspected cause of female-pattern hair loss?
2. Which clinical presentation is associated with female-pattern hair loss?
3. What is the first-line therapy for female-pattern hair loss?
4. Which laboratory test can help diagnose an underlying hyperandrogenic state in female-pattern hair loss?
5. What is the role of spironolactone in managing female-pattern hair loss?
6. What is a common side effect of flutamide?
7. Which type of medication is used for glaucoma but also causes eyelash growth as a side effect?
8. What is the primary characteristic of alopecia areata?
9. What is the first-line therapy for limited hair loss in alopecia areata?
10. Which medication is an alternative to triamcinolone acetonide for intralesional corticosteroid treatment in alopecia areata?
Hair loss in women can result from various factors, including hormonal imbalances, genetic predispositions, and autoimmune responses. Understanding the underlying causes and available treatments is crucial for effective management.
QuizRise is a free tool that allows you to create quizzes from any source. It's a great way to engage your audience and test their knowledge.
Let's get started